Status:
UNKNOWN
New Biomarkers in Pancreatic Cancer Using EXPEL Concept
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
IRCM U1194 INSERM, Tumor Microenvironment and Resistance to Treatment Lab
IRCM U1194 INSERM, Cancer Bioinformatics and Systems Biology's team
Conditions:
Oncology
Eligibility:
All Genders
18+ years
Brief Summary
The investigators recently engineered a novel biomarker discovery approach that is non-destructive and fully compatible with OMICS profiling as well as routine clinical procedures (5). The latter appr...
Detailed Description
Biomarkers that are readily detectable in fluid biopsies are of outmost importance for diagnosis and prediction of therapeutic response in all cancer patients. Pancreatic ductal adenocarcinoma (PDAC) ...
Eligibility Criteria
Inclusion
- Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy or surgery
- Patient ≥18 years old
- Patient naïve of any treatment of Pancreatic cancer
Exclusion
- Patient who reject the study protocol
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03791073
Start Date
January 1 2018
End Date
November 1 2024
Last Update
May 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295